Related Experiment Video

Updated: Jul 6, 2025

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

14.8K

Apigenin exerts anti-cancer effects in colon cancer by targeting HSP90AA1

Arindam Sain1, Dipshikha Khamrai1, Thirukumaran Kandasamy2

  • 1Department of Biotechnology, Maulana Abul Kalam Azad University of Technology, West Bengal, Nadia, West Bengal, India.

Journal of Biomolecular Structure & Dynamics
|December 29, 2023
PubMed

Insights

Apigenin shows promise for colon cancer (CC). This study identifies HSP90AA1 as a key target, demonstrating Apigenin

Area of Science:

  • Oncology
  • Pharmacology
  • Bioinformatics

Background:

  • Colon cancer (CC) remains a significant health concern.
  • Flavonoids, like Apigenin, are being investigated for their anti-cancer properties.
  • Understanding Apigenin's mechanisms in CC is crucial for therapeutic development.

Purpose of the Study:

  • To identify and validate molecular targets of Apigenin in colon cancer.
  • To explore the therapeutic potential of Apigenin and its metabolite, luteolin, against CC.
  • To elucidate the role of HSP90AA1 in Apigenin's anti-cancer effects.

Main Methods:

  • Bioinformatic analysis to identify shared targets between Apigenin and CC.
  • Functional enrichment analysis (Gene Ontology, KEGG) and protein-protein interaction network construction.
  • Molecular docking, molecular dynamics simulation, differential gene/protein expression analysis (TCGA data), and real-time PCR.

Main Results:

  • HSP90AA1, MMP9, and PTGS2 were identified as top potential targets.
  • HSP90AA1 and MMP9 expression were elevated in CC and linked to poor survival.
  • HSP90AA1 was confirmed as a primary target, with Apigenin reducing its expression and inducing cytotoxicity in CC cells.

Conclusions:

  • HSP90AA1 is a key molecular target for Apigenin's anti-colon cancer activity.
  • Apigenin and its metabolite luteolin exhibit anti-cancer effects against CC cells.
  • Apigenin holds potential as a therapeutic agent for colon cancer treatment.
Keywords:
ApigeninHSP90AA1MDScolon cancerluteolinmolecular docking

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

924

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K